Loading...

China Isotope & Radiation Corporation

1763.HK•HKSE
Healthcare
Medical - Devices
HK$18.96
HK$1.05(5.86%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the past four quarters, China Isotope & Radiation Corporation demonstrated steady revenue growth, increasing from $3.53B in Q4 2022 to $2.81B in Q2 2024. Operating income reached $409.43M in Q2 2024, maintaining a consistent 15% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $526.21M, reflecting operational efficiency. Net income dropped to $154.50M, with EPS at $0.48. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;